Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The operating income for Cadrenal Therapeutics, Inc. as of June 30, 2025 is -14.40 MM.
- The net income for Cadrenal Therapeutics, Inc. as of June 30, 2025 is -14.11 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | -14.40 | -14.11 | |
| 2025-03-31 | -13.13 | -12.83 | |
| 2024-12-31 | -10.96 | -10.65 | |
| 2024-09-30 | -7.95 | -7.61 | |
| 2024-06-30 | -6.63 | -6.24 | |
| 2024-03-31 | -5.19 | -4.85 | |
| 2023-12-31 | -7.63 | -8.36 | |
| 2023-09-30 | -7.69 | -12.83 | |
| 2023-06-30 | -7.52 | -12.82 | |
| 2023-03-31 | -6.98 | -12.32 | |
| 2022-12-31 | -2.95 | -7.32 |
Income Statement: EPS
- The earnings per share basic for Cadrenal Therapeutics, Inc. as of June 30, 2025 is -8.62.
- The earnings per share diluted for Cadrenal Therapeutics, Inc. as of June 30, 2025 is -8.62.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | -8.62 | -8.62 |
| 2025-03-31 | -9.08 | -9.08 |
| 2024-12-31 | -8.73 | |
| 2024-09-30 | -7.06 | -7.06 |
| 2024-06-30 | -5.89 | -5.89 |
| 2024-03-31 | -4.91 | -4.91 |
| 2023-12-31 | -9.29 | |
| 2023-09-30 | -16.68 | -16.68 |
| 2023-06-30 | -19.82 | -19.82 |
| 2023-03-31 | -21.22 | -21.22 |
| 2022-12-31 | -13.92 | -13.92 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Cadrenal Therapeutics, Inc. as of June 30, 2025 is -11.67 MM.
- The cash from investing activities for Cadrenal Therapeutics, Inc. as of June 30, 2025 is -0.01 MM.
- The cash from financing activities for Cadrenal Therapeutics, Inc. as of June 30, 2025 is 12.21 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -11.67 | -0.01 | 12.21 |
| 2025-03-31 | -10.17 | -0.01 | 10.95 |
| 2024-12-31 | -7.36 | -0.01 | 8.98 |
| 2024-09-30 | -6.26 | 0.00 | 1.52 |
| 2024-06-30 | -4.69 | -0.00 | 6.50 |
| 2024-03-31 | -3.95 | -0.00 | 6.50 |
| 2023-12-31 | -3.53 | -0.00 | 11.90 |
| 2023-09-30 | -3.24 | -0.00 | 12.25 |
| 2023-06-30 | -3.03 | -0.01 | 6.20 |
| 2023-03-31 | -2.68 | -0.00 | 6.25 |
| 2022-12-31 | -1.31 | -0.00 | 1.35 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/e for Cadrenal Therapeutics, Inc. as of June 30, 2025 is -1.79.
- The p/book for Cadrenal Therapeutics, Inc. as of June 30, 2025 is 3.76.
- The p/tbv for Cadrenal Therapeutics, Inc. as of June 30, 2025 is 3.76.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | -1.79 | 3.76 | 3.76 |
| 2025-03-31 | 4.66 | 4.66 | |
| 2024-12-31 | 7.43 | 7.43 | |
| 2024-09-30 | -2.52 | 3.93 | 3.93 |
| 2024-06-30 | -1.54 | 1.20 | 1.20 |
| 2024-03-31 | 1.33 | 1.33 | |
| 2023-12-31 | -0.75 | 1.10 | 1.10 |
| 2023-09-30 | -0.69 | 2.79 | 2.79 |
| 2023-06-30 | -1.41 | 4.28 | 4.28 |
| 2023-03-31 | -2.24 | -2.96 | |
| 2022-12-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for Cadrenal Therapeutics, Inc. as of June 30, 2025 is -0.82.
- The ebit (3y)/ev for Cadrenal Therapeutics, Inc. as of June 30, 2025 is -0.68.
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | -0.82 | -0.68 |
| 2025-03-31 | -0.43 | -0.38 |
| 2024-12-31 | -0.36 | -0.37 |
| 2024-09-30 | -0.59 | -0.60 |
| 2024-06-30 | -5.49 | -6.49 |
| 2024-03-31 | -4.66 | -1.55 |
| 2023-12-31 | -24.39 | -8.13 |
| 2023-09-30 | -2.28 | -0.76 |
| 2023-06-30 | -0.88 | -0.29 |
| 2023-03-31 | -0.43 | -0.14 |
| 2022-12-31 |
Management Effectiveness
- The roa for Cadrenal Therapeutics, Inc. as of June 30, 2025 is -2.35.
- The roe for Cadrenal Therapeutics, Inc. as of June 30, 2025 is -3.21.
- The roic for Cadrenal Therapeutics, Inc. as of June 30, 2025 is -2.10.
- The croic for Cadrenal Therapeutics, Inc. as of June 30, 2025 is 0.13.
- The ocroic for Cadrenal Therapeutics, Inc. as of June 30, 2025 is -1.66.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-30 | -2.35 | -3.21 | -2.10 | 0.13 | -1.66 |
| 2025-03-31 | -1.51 | -1.72 | -1.43 | 0.22 | -0.99 |
| 2024-12-31 | -0.89 | -0.99 | -2.23 | -1.39 | -1.83 |
| 2024-09-30 | -0.67 | -0.71 | -1.56 | 0.45 | -1.17 |
| 2024-06-30 | -1.08 | -1.19 | -0.78 | 0.41 | -0.64 |
| 2024-03-31 | -10.74 | -1.08 | 1.08 | -0.46 | |
| 2023-12-31 | -1.46 | 1.03 | -0.37 | ||
| 2023-09-30 | -4.00 | 0.99 | -0.94 | ||
| 2023-06-30 | -50.63 | -3.37 | 0.83 | -0.79 | |
| 2023-03-31 | -2.62 | 0.76 | |||
| 2022-12-31 |
Gross Margins
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 |
Identifiers and Descriptors
| Central Index Key (CIK) | 1937993 |
Industry Groups
| SIC 2834 - Pharmaceutical Preparations |
